No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)

Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in...

Descripción completa

Detalles Bibliográficos
Autores principales: Capelli, Laura, Casadei Gardini, Andrea, Scarpi, Emanuela, Frassineti, Giovanni Luca, Saragoni, Luca, Puccetti, Maurizio, Scartozzi, Mario, Giannini, Massimo, Tamberi, Stefano, Corbelli, Jody, Ulivi, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122846/
https://www.ncbi.nlm.nih.gov/pubmed/27886225
http://dx.doi.org/10.1038/srep37621
_version_ 1782469652609236992
author Capelli, Laura
Casadei Gardini, Andrea
Scarpi, Emanuela
Frassineti, Giovanni Luca
Saragoni, Luca
Puccetti, Maurizio
Scartozzi, Mario
Giannini, Massimo
Tamberi, Stefano
Corbelli, Jody
Ulivi, Paola
author_facet Capelli, Laura
Casadei Gardini, Andrea
Scarpi, Emanuela
Frassineti, Giovanni Luca
Saragoni, Luca
Puccetti, Maurizio
Scartozzi, Mario
Giannini, Massimo
Tamberi, Stefano
Corbelli, Jody
Ulivi, Paola
author_sort Capelli, Laura
collection PubMed
description Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in SCAC. In this study we analyzed NRAS status (exons 2–4) by Pyrosequencing in a case series of 50 SCAC patients previously characterized in our laboratory for KRAS, BRAF, PIK3CA mutations and HPV and HIV infections. We found no mutation in NRAS gene. These results confirm that since the principal anti-EGFR resistance mechanisms are almost absent in SCAC, anti-EGFR agents should be considered for the treatment of this type of cancer.
format Online
Article
Text
id pubmed-5122846
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51228462016-11-28 No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) Capelli, Laura Casadei Gardini, Andrea Scarpi, Emanuela Frassineti, Giovanni Luca Saragoni, Luca Puccetti, Maurizio Scartozzi, Mario Giannini, Massimo Tamberi, Stefano Corbelli, Jody Ulivi, Paola Sci Rep Article Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in SCAC. In this study we analyzed NRAS status (exons 2–4) by Pyrosequencing in a case series of 50 SCAC patients previously characterized in our laboratory for KRAS, BRAF, PIK3CA mutations and HPV and HIV infections. We found no mutation in NRAS gene. These results confirm that since the principal anti-EGFR resistance mechanisms are almost absent in SCAC, anti-EGFR agents should be considered for the treatment of this type of cancer. Nature Publishing Group 2016-11-25 /pmc/articles/PMC5122846/ /pubmed/27886225 http://dx.doi.org/10.1038/srep37621 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Capelli, Laura
Casadei Gardini, Andrea
Scarpi, Emanuela
Frassineti, Giovanni Luca
Saragoni, Luca
Puccetti, Maurizio
Scartozzi, Mario
Giannini, Massimo
Tamberi, Stefano
Corbelli, Jody
Ulivi, Paola
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
title No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
title_full No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
title_fullStr No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
title_full_unstemmed No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
title_short No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)
title_sort no evidence of nras mutation in squamous cell anal carcinoma (scac)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122846/
https://www.ncbi.nlm.nih.gov/pubmed/27886225
http://dx.doi.org/10.1038/srep37621
work_keys_str_mv AT capellilaura noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT casadeigardiniandrea noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT scarpiemanuela noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT frassinetigiovanniluca noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT saragoniluca noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT puccettimaurizio noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT scartozzimario noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT gianninimassimo noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT tamberistefano noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT corbellijody noevidenceofnrasmutationinsquamouscellanalcarcinomascac
AT ulivipaola noevidenceofnrasmutationinsquamouscellanalcarcinomascac

Ejemplares similares